1. Home
  2. IMMP vs STXS Comparison

IMMP vs STXS Comparison

Compare IMMP & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • STXS
  • Stock Information
  • Founded
  • IMMP 1987
  • STXS 1990
  • Country
  • IMMP Australia
  • STXS United States
  • Employees
  • IMMP N/A
  • STXS N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • IMMP Health Care
  • STXS Health Care
  • Exchange
  • IMMP Nasdaq
  • STXS Nasdaq
  • Market Cap
  • IMMP 251.8M
  • STXS 254.1M
  • IPO Year
  • IMMP N/A
  • STXS 2004
  • Fundamental
  • Price
  • IMMP $1.97
  • STXS $3.20
  • Analyst Decision
  • IMMP Buy
  • STXS
  • Analyst Count
  • IMMP 1
  • STXS 0
  • Target Price
  • IMMP $7.00
  • STXS N/A
  • AVG Volume (30 Days)
  • IMMP 120.6K
  • STXS 532.0K
  • Earning Date
  • IMMP 10-10-2025
  • STXS 11-10-2025
  • Dividend Yield
  • IMMP N/A
  • STXS N/A
  • EPS Growth
  • IMMP N/A
  • STXS N/A
  • EPS
  • IMMP N/A
  • STXS N/A
  • Revenue
  • IMMP $3,306,742.00
  • STXS $31,806,000.00
  • Revenue This Year
  • IMMP $16.82
  • STXS $30.98
  • Revenue Next Year
  • IMMP N/A
  • STXS $49.86
  • P/E Ratio
  • IMMP N/A
  • STXS N/A
  • Revenue Growth
  • IMMP 31.28
  • STXS 33.94
  • 52 Week Low
  • IMMP $1.32
  • STXS $1.54
  • 52 Week High
  • IMMP $2.71
  • STXS $3.59
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 63.51
  • STXS 57.26
  • Support Level
  • IMMP $1.75
  • STXS $3.16
  • Resistance Level
  • IMMP $2.10
  • STXS $3.59
  • Average True Range (ATR)
  • IMMP 0.09
  • STXS 0.18
  • MACD
  • IMMP 0.03
  • STXS 0.02
  • Stochastic Oscillator
  • IMMP 74.79
  • STXS 48.65

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Share on Social Networks: